[Angiogenesis targeting in gastro-intestinal cancers]

Area of Science:

• Oncology
• Medical Research

Background:

• Colorectal cancer is the first malignancy to show significant benefit from anti-angiogenic therapy.
• Bevacizumab is approved for first-line metastatic colorectal cancer treatment in combination with chemotherapy.
• Anti-angiogenic therapy is under investigation for adjuvant settings in colorectal cancer.

Purpose of the Study:

• To review the efficacy and safety of anti-angiogenic treatments in gastrointestinal malignancies.
• To discuss the development of VEGF receptor inhibitors for other GI cancers.
• To highlight the distinct safety profiles of anti-angiogenic agents compared to traditional chemotherapy.

Main Methods:

• Review of current clinical data and research on anti-angiogenic therapies in GI cancers.
• Analysis of approved treatments and ongoing clinical trials.
• Comparison of safety profiles between anti-angiogenic agents and chemotherapy.

Main Results:

• Bevacizumab demonstrates efficacy in metastatic colorectal cancer.
• Other gastrointestinal malignancies show varied responses to anti-angiogenic therapy.
• VEGF receptor inhibitors (sorafenib, sunitinib, axitinib) show promising results in development.

Conclusions:

• Anti-angiogenic therapy, particularly bevacizumab, has significantly impacted colorectal cancer treatment.
• Further research and development of VEGF receptor inhibitors are ongoing for other GI cancers.
• The unique safety profile of anti-angiogenic agents necessitates modified treatment strategies.